Abstract
With highly active antiretroviral therapy (ART), people living with HIV can achieve and maintain viral suppression below a detectable level, preventing transmission of HIV and AIDS-related mortality.1,2 However, persistent low-level viraemia (usually defined as plasma HIV-RNA between 50 copies per mL to below the threshold for virological failure) occurs among some people living with HIV receiving ART.3–5 Despite its occurrence, the clinical significance and management of low-level viraemia remains unclear,3,5,6 particularly with dolutegravir-based ART regimen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
